DD
Therapeutic Areas
Telix Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Illuccix®/Gozellix® (TLX591-CDx) | Prostate Cancer (PSMA-PET Imaging) | Approved |
| TLX591 (177Lu-DOTA-rosopatamab) | Prostate Cancer (mCRPC) | Phase 3 |
| TLX101 (Pixclara® / 131I-IPA) | Glioblastoma (GBM) | Phase 3 |
| TLX250 (177Lu-girentuximab) | Renal Cell Carcinoma (ccRCC) | Phase 3 |
| TLX250-CDx (89Zr-girentuximab) | Renal Cell Carcinoma (ccRCC) Imaging | Phase 3 |
| TLX301 (177Lu-DOTA-rituximab) | B-Cell Conditioning (Bone Marrow) | Phase 3 |
| TLX101-CDx (123I-IPA) | Glioblastoma Imaging | Phase 2/3 |
| SENSEI® Gamma Probe | Surgical Guidance | Marketed |
Leadership Team at Telix Pharmaceuticals
DC
Dr Christian Behrenbruch
Managing Director & Group Chief Executive Officer
MN
Mark Nelson
Non-Executive Director and Interim Chair
MM
Marie McDonald
Independent Non-Executive Director
JS
Jann Skinner
Independent Non-Executive Director
GR
Genevieve Ryan
Company Secretary
DS
Darren Smith
Group Chief Financial Officer
MJ
Mary Jessel
Group Chief of Clinical Affairs
CK
Christian Krautkramer
Group General Counsel
RV
Richard Valeix
Chief Executive Officer, Telix Therapeutics
KR
Kevin Richardson
Chief Executive Officer, Telix Precision Medicine